S&P 500   4,585.69 (+0.75%)
DOW   35,630.60 (+0.39%)
QQQ   383.85 (+1.01%)
AAPL   152.72 (+2.60%)
MSFT   323.98 (+0.25%)
FB   315.87 (+1.17%)
GOOGL   2,926.76 (+0.08%)
TSLA   1,073.54 (+3.44%)
AMZN   3,477.10 (+2.49%)
NVDA   246.37 (+0.76%)
BABA   169.99 (+0.45%)
NIO   39.87 (+1.42%)
CGC   12.98 (+1.56%)
GE   104.24 (+0.38%)
AMD   120.70 (-1.29%)
MU   69.67 (+2.10%)
T   25.55 (+1.96%)
F   16.77 (+8.12%)
ACB   6.94 (+1.46%)
DIS   170.01 (+0.27%)
PFE   43.15 (+0.42%)
BA   206.68 (+0.03%)
AMC   35.26 (+1.44%)
S&P 500   4,585.69 (+0.75%)
DOW   35,630.60 (+0.39%)
QQQ   383.85 (+1.01%)
AAPL   152.72 (+2.60%)
MSFT   323.98 (+0.25%)
FB   315.87 (+1.17%)
GOOGL   2,926.76 (+0.08%)
TSLA   1,073.54 (+3.44%)
AMZN   3,477.10 (+2.49%)
NVDA   246.37 (+0.76%)
BABA   169.99 (+0.45%)
NIO   39.87 (+1.42%)
CGC   12.98 (+1.56%)
GE   104.24 (+0.38%)
AMD   120.70 (-1.29%)
MU   69.67 (+2.10%)
T   25.55 (+1.96%)
F   16.77 (+8.12%)
ACB   6.94 (+1.46%)
DIS   170.01 (+0.27%)
PFE   43.15 (+0.42%)
BA   206.68 (+0.03%)
AMC   35.26 (+1.44%)
S&P 500   4,585.69 (+0.75%)
DOW   35,630.60 (+0.39%)
QQQ   383.85 (+1.01%)
AAPL   152.72 (+2.60%)
MSFT   323.98 (+0.25%)
FB   315.87 (+1.17%)
GOOGL   2,926.76 (+0.08%)
TSLA   1,073.54 (+3.44%)
AMZN   3,477.10 (+2.49%)
NVDA   246.37 (+0.76%)
BABA   169.99 (+0.45%)
NIO   39.87 (+1.42%)
CGC   12.98 (+1.56%)
GE   104.24 (+0.38%)
AMD   120.70 (-1.29%)
MU   69.67 (+2.10%)
T   25.55 (+1.96%)
F   16.77 (+8.12%)
ACB   6.94 (+1.46%)
DIS   170.01 (+0.27%)
PFE   43.15 (+0.42%)
BA   206.68 (+0.03%)
AMC   35.26 (+1.44%)
S&P 500   4,585.69 (+0.75%)
DOW   35,630.60 (+0.39%)
QQQ   383.85 (+1.01%)
AAPL   152.72 (+2.60%)
MSFT   323.98 (+0.25%)
FB   315.87 (+1.17%)
GOOGL   2,926.76 (+0.08%)
TSLA   1,073.54 (+3.44%)
AMZN   3,477.10 (+2.49%)
NVDA   246.37 (+0.76%)
BABA   169.99 (+0.45%)
NIO   39.87 (+1.42%)
CGC   12.98 (+1.56%)
GE   104.24 (+0.38%)
AMD   120.70 (-1.29%)
MU   69.67 (+2.10%)
T   25.55 (+1.96%)
F   16.77 (+8.12%)
ACB   6.94 (+1.46%)
DIS   170.01 (+0.27%)
PFE   43.15 (+0.42%)
BA   206.68 (+0.03%)
AMC   35.26 (+1.44%)
NASDAQ:INMD

InMode Stock Forecast, Price & News

$87.92
+5.08 (+6.13 %)
(As of 10/28/2021 12:27 PM ET)
Add
Compare
Today's Range
$83.45
$88.50
50-Day Range
$52.51
$159.45
52-Week Range
$18.02
$91.00
Volume
26,586 shs
Average Volume
1.62 million shs
Market Capitalization
$5.62 billion
P/E Ratio
58.61
Dividend Yield
N/A
Beta
1.65
30 days | 90 days | 365 days | Advanced Chart
Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.


InMode logo

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMD
Employees
311
Year Founded
2008

Sales & Book Value

Annual Sales
$206.11 million
Cash Flow
$1.23 per share
Book Value
$4.00 per share

Profitability

Net Income
$75.03 million
Pretax Margin
45.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$5.62 billion
Next Earnings Date
2/9/2022 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

Social Links


MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

1129th out of 1,372 stocks

Electromedical Equipment Industry

26th out of 31 stocks

Analyst Opinion: 1.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












InMode (NASDAQ:INMD) Frequently Asked Questions

Is InMode a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" InMode stock.
View analyst ratings for InMode
or view top-rated stocks.

What stocks does MarketBeat like better than InMode?

Wall Street analysts have given InMode a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMode wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InMode?

InMode saw a increase in short interest in September. As of September 30th, there was short interest totaling 2,930,000 shares, an increase of 110.8% from the September 15th total of 1,390,000 shares. Based on an average daily volume of 1,920,000 shares, the days-to-cover ratio is presently 1.5 days.
View InMode's Short Interest
.

When is InMode's next earnings date?

InMode is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for InMode
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) announced its quarterly earnings data on Tuesday, October, 26th. The healthcare company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The healthcare company had revenue of $94.18 million for the quarter, compared to the consensus estimate of $89.38 million. InMode had a trailing twelve-month return on equity of 45.87% and a net margin of 44.34%. The firm's revenue was up 57.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.31 EPS.
View InMode's earnings history
.

How has InMode's stock price been impacted by COVID-19 (Coronavirus)?

InMode's stock was trading at $12.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INMD shares have increased by 614.3% and is now trading at $87.15.
View which stocks have been most impacted by COVID-19
.

When did InMode's stock split? How did InMode's stock split work?

InMode's stock split before market open on Friday, October 1st 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were payable to shareholders after the market closes on Thursday, September 30th 2021. An investor that had 100 shares of InMode stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode issued an update on its FY21 earnings guidance on Tuesday, October, 26th. The company provided earnings per share (EPS) guidance of $1.91-$1.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.86. The company issued revenue guidance of $343-$347 million, compared to the consensus revenue estimate of $339.54 million.

What price target have analysts set for INMD?

5 Wall Street analysts have issued 1-year price objectives for InMode's stock. Their forecasts range from $42.00 to $103.00. On average, they anticipate InMode's stock price to reach $85.20 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts' price targets for InMode
or view top-rated stocks among Wall Street analysts.

Who are InMode's key executives?

InMode's management team includes the following people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 68, Pay $216k)
  • Mr. Yair Malca, Chief Financial Officer (Age 43, Pay $429k)
  • Dr. Michael Kreindel, CTO & Director (Age 53, Pay $217k)
  • Mr. Shakil Lakhani, Pres of North America (Age 38, Pay $2.05M)
  • Dr. Spero Theodorou M.D., Chief Medical Officer (Age 49, Pay $1.62M)

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode CEO Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among InMode's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a variety of retail and institutional investors. Top institutional investors include Obermeyer Wood Investment Counsel Lllp (0.51%), Redwood Investments LLC (0.27%), Baltimore Washington Financial Advisors Inc. (0.23%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.18%), Spire Wealth Management (0.00%) and Hodges Capital Management Inc. (0.32%).

Which institutional investors are selling InMode stock?

INMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Taylor Frigon Capital Management LLC, State of New Jersey Common Pension Fund D, Redwood Investments LLC, Avantax Advisory Services Inc., Hellman Jordan Management Co. Inc. MA, Cornerstone Investment Partners LLC, and Park Avenue Securities LLC.

Which institutional investors are buying InMode stock?

INMD stock was bought by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management , Spire Wealth Management, David J Yvars Group, Meritage Portfolio Management, Hodges Capital Management Inc., Nkcfo LLC, Samson Rock Capital LLP, and Obermeyer Wood Investment Counsel Lllp.

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $87.15.

How much money does InMode make?

InMode has a market capitalization of $5.57 billion and generates $206.11 million in revenue each year.

How many employees does InMode have?

InMode employs 311 workers across the globe.

Does InMode have any subsidiaries?

The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..

When was InMode founded?

InMode was founded in 2008.

What is InMode's official website?

The official website for InMode is www.inmodemd.com.

Where are InMode's headquarters?

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-7470 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.